From The Editor

  1. The Challenge Of Getting Cell Therapies To Patients

    Current cell therapies are both exciting and promising. However, delivering them to a larger pool of patients will prove to be a complicated proposition.

  2. Biohacking: Bringing Patient Centricity To Biologics Drug Development

    The insulin market has yet to see generic competition. However, one team of scientists known as biohackers aims to identify a cost-effective protocol for the development of biosimilar wild-type insulin. Getting this treatment approved for market use may not be the primary goal for this group, but the Open Insulin project speaks volumes about the role patients and regular citizens can play in modern drug development.  

  3. What Amgen And Biosimilar Makers Stand To Gain From AbbVie’s IPR Win

    Amgen's IPR upset is being viewed as a big setback for the biosimilar industry. However, when considering the fact that Amgen is both an innovator and biosimilar maker, this loss carries with it an interesting benefit for the biosimilar industry.

  4. 4 Takeaways From Cell & Gene Therapy World

    Cell and gene therapies hold great promise for patients. Now, the pressure is on the industry to develop processes and solutions that deliver these products economically.

  5. UPS Pain In The Chain Survey: Pharma Makes Gains In Compliance, Partnerships

    UPS' Pain in the Chain survey is one of the best ways to understand where life science companies stand on the issues making logistics a headache and keeping executives up at night. Since 2008, the survey of healthcare and life science supply chain professionals has attempted to determine the needs of these companies.

  6. Cinfa Biotech: How Pharmacists Can Benefit Biosimilar Development

    Developing a biosimilar is a highly scientific process. To ensure the biosimilar demonstrates the same efficacy and safety profile as the reference product, the science and clinical data have to match up. However, as Ruediger Jankowsky, managing director of Cinfa Biotech, says, a company should approach biosimilars from the “pharmacist’s perspective,” which extends far beyond the science of a biosimilar.

  7. Should The Biosimilar Industry Worry Over AbbVie’s IPR Triumph?

    In the face of biosimilar competition, AbbVie has been outspoken about Humira's IP protection. After last week when the PTAB dismissed Amgen’s IPRs against two of Humira’s patents, the biosimilar industry is likely feeling the impact of AbbVie’s IP investments. Could this decision be a major setback for the development of the biosimilar market moving forward?  

  8. EPIRUS Biopharmaceuticals: What Biosimilars Can Learn From The Generics Market

    Though differentiating large-molecule biosimilars from small molecule generics is a staple in biosimilar education, Amit Munshi, CEO of pure-play biosimilar company EPIRUS Biopharmaceuticals, argues the history of the generics market could hold valuable clues as to how the biosimilar market will evolve.

  9. What Biosimilar Makers Need To Know About 2016

    Over the past few weeks, I've been reading predictions of what pharma is going to look like in 2016. Here are a few of the key developments and trends that are going to be especially important for those building a business around biosimilars to keep in mind.

  10. Biopharma Trends That Will Impact You In 2016

    December is coming to a close, which means a new year is right around the corner, bringing new challenges and new opportunities. I recently spoke to industry experts who offered some insight on the key trends in 2016 that are expected to shape the year ahead and have a significant impact on the future of biopharma.